Clinical Trials Browser

Terminated × INDUSTRY × siltuximab × Clear all

NCT00385827 2014-08-20

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Phase 2 Terminated

106 enrolled 13 charts

Neoplasms, Prostatic Neoplasms

NCT01309412 2014-05-19

A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma, Recurrence